



IMI HARMONY – Big Data in treating Hematologic Malignancies

The HARMONY Alliance: European Network of Excellence for Big Data in Hematology.

This abstract was developed for the [2nd Annual Conference of the ÖPPM](#), the Austrian Platform for Personalized Medicine.

The HARMONY Alliance is a European Public-Private Network of Excellence for Big Data in Hematology, consisting of 53 Partners and 27 Associated Members. HARMONY focuses on blood cancers with unmet clinical needs. HARMONY has developed a data platform that will register outcome measures that are relevant to different groups of stakeholders, such as physicians, patients, data scientists, drug developers, policy makers and regulators.

Blood cancers, or hematologic malignancies, affect the production and function of blood cells and account for about 40% of cancer cases in children and about one third of cancer deaths.

As many blood cancers are rare, and healthcare practice varies across EU, a lack of data on relevant outcomes represents a challenge for clinicians, researchers, and other decision-makers like regulators and HTA bodies, resulting in limitations for patient access to the best healthcare. HARMONY aims to use "Big Data and Big Data analytics" to deliver information that will help to improve the care of patients with these diseases. HARMONY gathers, integrates and analyzes anonymous patient data from high-quality sources. This will help defining clinical endpoints and outcomes for these diseases, which are recognized by all key stakeholders in the Healthcare - systems. Meanwhile, the insights generated by HARMONY will facilitate and improve decision-making along the value chain in order to ultimately give the right treatment to the right patient at the right time.

HARMONY focuses on the following seven hematologic malignancies: Acute lymphoblastic leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myelodysplastic Syndromes, Non-Hodgkins Lymphoma, Multiple Myeloma and Pediatric Hematologic Malignancies.

The HARMONY Alliance was established in January 2017 and will last for a period of 5 years. HARMONY is funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients.



HARMONY has received funding from IMI 2 Joint Undertaking and is listed under grant agreement No. 116026. This Joint Undertaking receives support from the European Union's Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe.

At [ÖPPM 2018](#) the HARMONY Alliance is represented by Christiane Druml and Klaus Wassermann from the Medical University of Vienna.
Dr. Druml is Leader of [HARMONY Work Package 8: Legal Issues, Ethics, and Governance](#).

www.harmony-alliance.eu | [@HarmonyNetEU](#) | [LinkedIn](#)

HARMONY Communication Office:

Ellen de Waal, communications@harmony-alliance.eu

HARMONY Coordination Office:

Santiago Moralejo del Arco, Harmonyoffice@ibsal.es

Funded through the Innovative Medicines Initiative (IMI) 2 Joint Undertaking and listed under grant agreement No. 116026. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

